It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The selective autophagy of damaged mitochondria is called mitophagy. Mitochondrial dysfunction, mitophagy, and apoptosis have been suggested to be interrelated in various human lung carcinomas. Leucine zipper EF-hand-containing transmembrane protein-1 (LETM1) was cloned in an attempt to identify candidate genes for Wolf–Hirschhorn syndrome. LETM1 plays a role in mitochondrial morphology, ion homeostasis, and cell viability. LETM1 has also been shown to be overexpressed in different human cancer tissues, including lung cancer. In the current study, we have provided clear evidence that LETM1 acts as an anchoring protein for the mitochondria-associated ER membrane (MAM). Fragmented mitochondria have been found in lung cancer cells with LETM1 overexpression. In addition, a reduction of mitochondrial membrane potential and significant accumulation of microtubule-associated protein 1 A/1B-light chain 3 punctate, which localizes with Red-Mito, was found in LETM1-overexpressed cells, suggesting that mitophagy is upregulated in these cells. Interestingly, glucose-regulated protein 78 kDa (GRP78; an ER chaperon protein) and glucose-regulated protein 75 kDa (GRP75) were posited to interact with LETM1 in the immunoprecipitated LETM1 of H460 cells. This interaction was enhanced in cells treated with carbonyl cyanide m-chlorophenylhydrazone, a chemical mitophagy inducer. Treatment of cells with honokiol (a GRP78 inhibitor) blocked LETM1-mediated mitophagy, and CRISPR/Cas9-mediated GRP75 knockout inhibited LETM1-induced autophagy. Thus, GRP78 interacts with LETM1. Taken together, these observations support the notion that the complex formation of LETM1/GRP75/GRP78 might be an important step in MAM formation and mitophagy, thus regulating mitochondrial quality control in lung cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Chungnam National University, Department of Pharmacology, College of Medicine, Daejeon, South Korea (GRID:grid.254230.2) (ISNI:0000 0001 0722 6377); Chungnam National University, Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Daejeon, South Korea (GRID:grid.254230.2) (ISNI:0000 0001 0722 6377); Hai Phong International Hospital, Molecular Biology Laboratory, Department of Medical Laboratories, Hai Phong City, Vietnam (GRID:grid.254230.2)
2 Chungnam National University, Department of Pharmacology, College of Medicine, Daejeon, South Korea (GRID:grid.254230.2) (ISNI:0000 0001 0722 6377); Chungnam National University, Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Daejeon, South Korea (GRID:grid.254230.2) (ISNI:0000 0001 0722 6377)
3 Kyunghee University, Department of Applied Chemistry, College of Applied Sciences, Yongin, South Korea (GRID:grid.289247.2) (ISNI:0000 0001 2171 7818)
4 College of Veterinary Medicine Seoul National University, Laboratory of Toxicology, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
5 Chungnam National University, Department of Pharmacology, College of Medicine, Daejeon, South Korea (GRID:grid.254230.2) (ISNI:0000 0001 0722 6377); Chungnam National University, Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Daejeon, South Korea (GRID:grid.254230.2) (ISNI:0000 0001 0722 6377); Daejeon University, Department of Life Science, Hyehwa Liberal Arts College, Daejeon, South Korea (GRID:grid.411948.1) (ISNI:0000 0001 0523 5122)
6 Chungnam National University, Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Daejeon, South Korea (GRID:grid.254230.2) (ISNI:0000 0001 0722 6377)
7 Yonsei University Wonju College of Medicine, Department of Physiology and Institute of Lifestyle Medicine, Wonju, Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
8 Ulsan National Institute of Science and Technology, Department of Chemistry, Ulsan, Korea (GRID:grid.42687.3f) (ISNI:0000 0004 0381 814X)
9 Dong-A University, Mitochondria Hub Regulation Center, College of Medicine, Busan, South Korea (GRID:grid.255166.3) (ISNI:0000 0001 2218 7142)
10 College of Veterinary Medicine Seoul National University, Laboratory of Toxicology, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); RNABIO, Seongnam, South Korea (GRID:grid.31501.36)